Hostname: page-component-76fb5796d-2lccl Total loading time: 0 Render date: 2024-04-29T18:27:09.335Z Has data issue: false hasContentIssue false
  • English
  • Français

Ssri-related toxic serotonin syndrome: improvement by discontinuation of treatment and propranolol

Published online by Cambridge University Press:  16 April 2020

SM Dursun ,
JG Burke ,
F Nielsen ,
A Mlynik-Szmid  and
MA Reveley
SM Dursun*
Affiliation:
Department of Psychiatry, Faculty of Medicine, University of Leicester, Leicester, LE2 7LX, UK
JG Burke
Affiliation:
Department of Psychiatry, Faculty of Medicine, University of Leicester, Leicester, LE2 7LX, UK
F Nielsen
Affiliation:
Department of Psychiatry, Faculty of Medicine, University of Leicester, Leicester, LE2 7LX, UK
A Mlynik-Szmid
Affiliation:
Department of Psychiatry, Faculty of Medicine, University of Leicester, Leicester, LE2 7LX, UK
MA Reveley
Affiliation:
Department of Psychiatry, Faculty of Medicine, University of Leicester, Leicester, LE2 7LX, UK
*
*Correspondence and reprints: Department of Psychiatry, Dalhousie University, QEII HSC, AJLB, 4th Floor, Suite 4018, 5909 Jubilee Road, Halifax, NS B3H 2EZ, Canada.
Get access

Summary

We report three cases in which toxic serotonin syndrome developed in relation to three different selective serotonin reuptake inhibitors (SSRI) (ie, fluoxetine, sertraline, paroxetine), and which all responded to the discontinuation of the SSRI and also to an additional propranolol treatment.

Keywords

serotonin syndromeSSRItoxicpropranolol
Type
Short communication
Information
European Psychiatry , Volume 12 , Issue 6 , 1997 , pp. 321 - 323
Copyright
Copyright © European Psychiatric Association 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Dursun, SMMathew, VMReveley, MAToxic serotonin syn-drome after fluoxetine plus carbamazepine. Lancet 1993; 342: 442–443CrossRefGoogle Scholar
Dursun, SMBurke, JGReveley, MAToxic serotonin syndrome or extrapyramidal side-effects. Br J Psychiatry 1995; 116: 401–402CrossRefGoogle Scholar
Green, ARHeal, DJThe effects of drugs on serotonin mediated behavioural models In: Green, AR eds. Neuropharmacology of Serotonin Oxford: Oxford University Press, 1985 326–365Google Scholar
Guze, BHBaxter, LRThe serotonin syndrome: case responsive to propranolol. J Clin Psychopharmacol 1986; 6: 119–120CrossRefGoogle ScholarPubMed
Radomski, JWDursun, SMReveley, MAToxic serotonin syndrome: an update and revised diagnostic criteria J Psychopharm 93 suppl 1995 A21Google Scholar
Sprouse, JSAghajanian, GKPropranolol blocks the inhibition of serotonergic dorsal raphe cell firing by 5-HT1A selective agonists. Eur J Pharmacol 1986; 128: 295–298CrossRefGoogle ScholarPubMed
Sternbach, HThe serotonin syndrome. Am J Psychiatry 1991; 148: 705–713Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.